The treatment and prognosis analysis of KRAS single mutation and KRAS/TP53 co-mutation in lung adenocarcinoma
Objective:To compare the treatment and prognosis of kirsten rat sarcoma viral oncogene(KRAS)mu-tant lung adenocarcinoma patients with different mutation states and molecular typing.Methods:The data of patients with advanced KRAS mutant lung adenocarcinoma who were diagnosed and received first-line therapy in the First Affili-ated Hospital of Bengbu Medical College from April 2019 to April 2022 were collected.The co-mutation of TP53,mo-lecular typing and the correlation of treatment prognosis were analyzed.Results:Follow-up to April 2022,the mPFS of patients with KRAS/TP53 co-mutation was significantly shorterthan that of patients with KRAS single mutation(HR= 0.613,95%CI:0.396-0.951,P=0.029),and the difference was statistically significant.The mPFS of chemothera-py combined with anti-angiogenesis therapy was significantly prolonger than that of chemotherapy alone(HR=0.593,95%CI:0.355-0.990,P=0.038).The mPFS of chemotherapy combined with immunotherapy group was significant-ly longer than that of chemotherapy alone(HR=0.426,95%CI:0.247-0.736,P=0.02).There was no significant difference in mPFS between chemotherapy combined with anti-angiogenesis therapy group and chemotherapy combined with immunotherapy group(HR=0.648,95%CI:0.371-1.130,P=0.126).Conclusion:TP53 is a poor prognos-tic factor in patients with advanced KRAS mutant lung adenocarcinoma.There is no significant difference in treatment and prognosis between different molecular subtypes of G12C and non-G12C.Chemotherapy combined with immunother-apy or anti-angiogenesis therapy can prolong PFS in patients with advanced lung adenocarcinoma compared with chemo-therapy alone,but there is no significant difference in PFS between the combined treatment groups.
NETL
NSTL
万方数据
维普
